Matthew Call
2021
In 2021, Matthew Call earned a total compensation of $4.2M as Chief Operating Officer at iTeos Therapeutics.
Compensation breakdown
| Non-Equity Incentive Plan | $193,902 |
|---|---|
| Option Awards | $3,596,897 |
| Salary | $424,531 |
| Other | $8,550 |
| Total | $4,223,880 |
Call received $3.6M in option awards, accounting for 85% of the total pay in 2021.
Call also received $193.9K in non-equity incentive plan, $424.5K in salary and $8.6K in other compensation.
Rankings
In 2021, Matthew Call's compensation ranked 3,156th out of 12,415 executives tracked by ExecPay. In other words, Call earned more than 74.6% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 3,156 out of 12,415 | 75th |
Division Manufacturing | 1,272 out of 5,508 | 77th |
Major group Chemicals And Allied Products | 520 out of 2,378 | 78th |
Industry group Drugs | 461 out of 2,099 | 78th |
Industry Biological Products, Except Diagnostic Substances | 125 out of 449 | 72nd |
Source: SEC filing on April 25, 2022.
Call's colleagues
We found two more compensation records of executives who worked with Matthew Call at iTeos Therapeutics in 2021.